Expert Interviews

The expert panel discusses how MRD positivity affects treatment decisions for patients with colorectal cancer.

Experts on colorectal cancer present a patient case, offer their initial impressions, and discuss disease staging.

Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.

Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.

Daniel Pollyea, MD, MS, discusses how he assesses patients with newly diagnosed acute myeloid leukemia for the best first-line therapy, including the role of intensive induction chemotherapy.

Eunice S. Wang, MD, offers an overview of common barriers to performing molecular testing in community practices, including uncertainty about which tests to perform and the wait times for results.

Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.

Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.

In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.